美国ImaginAb
ImaginAb 是一间私营的生物技术公司，其致力于发展以特殊设计的抗体为基础之新式标靶诊断成像技术。ImaginAb将治疗用抗体改造为PK最佳化后的惰性片段，以制造出新式体内诊断成像技术用的试剂。ImaginAb提供其商业服务给生物制药公司，并正在努力发展针对癌症与自体免疫疾病使用的分子成像产品。

ImaginAb is a privately held U.S. biotechnology company based in Los Angeles, CA, focused on re-engineering antibodies into smaller protein formats with kinetics optimized for diagnostic imaging.

The company has two business units. Firstly, we have a superb pipeline of clinical imaging agents for oncology and immunology. There are many unmet clinical diagnostic needs in cancer and autoimmune diseases and this is reflected in our portfolio. Our two lead products for prostate cancer and pancreatic cancer commence clinical trials in 2012.

Our second major business segment is through our pharma partnering program. ImaginAb currently has over a dozen collaborations with global pharmaceutical companies to develop bespoke companion imaging agents based on therapeutic antibody pipelines. Our technology enables a therapeutic mAb or ADC to be re-engineered into an imaging agent that has all the biospecificity of the “parent” product but with kinetics suitable for clinical imaging with low-cost isotopes. This is a transformative technology for patient selection, monitoring treatment response and “indication scouting.”

The company was founded in October 2007 by Anna Wu, Rob Reiter, Chris Behrenbruch and Tove Olafsen. The company’s scientific and clinical origins are UCLA and the City of Hope (Duarte, CA). In March 2012, ImaginAb announced that the company closed $12.5m in financing led by Novartis Venture Fund (NVF).